TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9857856
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of imidapril
Study: 30592997
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg)
Study: 1419076
Drug: PGE2 infusion
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 infusion
Study: 28206704
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks (Q2W), increased to 150 mg Q2W at Week 12 if Week 8 LDL-C was ≥70 mg/dL
Study: 26929777
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg daily
Study: 23150188
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (EGB 761) 60 mg twice daily
Study: 17448130
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Intensive Lifestyle Intervention
Study: 12243825
Drug: GM-CSF mouthwashes
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF mouthwashes (37.5 microg GM-CSF, 4 times daily)
Study: 12243825
Drug: Sucralfate mouthwashes
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate mouthwashes (1.0 g sucralfate, 4 times daily)
Study: 9852907
Drug: Adenosine 15
Normalized name: ADENOSINE 15 g in 100 mL VAGINAL LIQUID [INNER SAVE Feminine Cleansing Mist]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 15 mumol/L
Study: 21083590
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg for 2 weeks
Study: 20084725
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin 80 mg/m2 on day 1 and Gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks) followed by radiotherapy (60 Gy/30 fractions/6 weeks)
Study: 9669077
Drug: Xylocaine (lidocaine)
Normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine (lidocaine) spray
Study: 9669077
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline spray
Study: 12472516
Drug: No spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: No spray
Study: 7641121
Drug: Tenormin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenormin (100 mg once daily)
Study: 7641121
Drug: Tenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenolol (100 mg once daily)
Study: 30307122
Drug: 7-day STT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day STT (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 7 days)
Study: 30307122
Drug: 7-day STT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day STT with bismuth (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, bismuth subcitrate 240 mg twice daily for 7 days)
Study: 25604851
Drug: mDCF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDCF regimen (docetaxel 60 mg/m² on day 1, cisplatin 60 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Study: 25604851
Drug: CF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF regimen (cisplatin 75 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Study: 25348033
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 200 to 400 mg per day
Study: 30022544
Drug: MAL cream
Normalized name: PLO Transdermal Cream
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL cream
Study: 18459010
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day for the first 2 years and 10 mg/day thereafter)
Study: 12473087
Drug: Physostigmine (cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (cholinesterase inhibitor)
Study: 1618254
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (Control)
Study: 25560423
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen
Study: 25082117
Drug: Olanzapine as
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine as an adjunct to lithium
Study: 25082117
Drug: Chlorpromazine as
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine as an adjunct to lithium
Study: 17852792
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg/day)
Study: 14748765
Drug: HRT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (oral 17beta‐estradiol 1 or 2 mg/day, plus cyclic dydrogesterone 10 mg)
Study: 14748765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin and HRT
Study: 8256080
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg salbutamol
Study: 8008027
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (25 mg daily)
Study: 8008027
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (1 g daily) and E (400 mg daily)
Study: 31923632
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with methylene blue and 660 nm diode laser (25 mW, dose: 19.23 J/CM2, probe diameter: 0.78 cm2) for three sessions (day 1, 3, 5)
Study: 31923632
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment on control side
Study: 31537217
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT), keeping blood glucose at 4.4-7.8 mmol/L
Study: 31537217
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic therapy (CGT), keeping blood glucose at 7.8-12.2 mmol/L
Study: 26307899
Drug: Basal Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal Bolus insulin regimen (glargine once daily and glulisine before meals)
Study: 24199923
Drug: Laparoscopy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopy combined with Leuprolide acetate (3.75 mg every 28 days)
Study: 24199923
Drug: Laparoscopy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopy combined with Goserelin acetate (3.6 mg every 28 days)
Study: 16434174
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 1000 microg daily
Study: 16434174
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg bid
Study: 8933545
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day)
Study: 8933545
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (30 mg/kg/day)
Study: 9215819
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 and Epirubicin 90 mg/m2
Study: 9164208
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m2
Study: 9215819
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 to 225 mg/m2
Study: 9215819
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and 225 mg/m2
Study: 9215819
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Epirubicin combination
Study: 17658985
Drug: Immediate Treatment
Normalized name: Aquaphor Immediate Relief Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Treatment (IT)
Study: 25678057
Drug: Conventional cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cardiac resynchronization therapy (CONV)
Study: 19291085
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of treatment
Study: 18349405
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m(2))
Study: 8726152
Drug: Sedated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedated with chloral hydrate, inhaled aerosol of 7.7 microns mass median diameter (MMD)
Study: 1444308
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (500 mg) with DR-3355 (100 mg)
Study: 1444308
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (160 mg) with DR-3355 (100 mg)
Study: 1444308
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1 g) with DR-3355 (100 mg)
Study: 1444308
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) with DR-3355 (100 mg)
Study: 1444308
Drug: DR-3355 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR-3355 (100 mg) alone
Study: 24576321
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (200 mW) at 2 J
Study: 24576321
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (200 mW) at 6 J
Study: 24576321
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (200 mW) at 10 J
Study: 17655657
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg without counseling on sexual side effects (group 1)
Study: 10051060
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (VPA) 2000 mg
Study: 25692980
Drug: Yacon-based product
Normalized name: 4XLA Base Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon-based product (YBP) with 10 g fructooligosaccharide (FOS)/inulin per day in orange juice
Study: 25692980
Drug: Maltodextrin in
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin in orange juice (control) with 25 g per day
Study: 23065117
Drug: Melodic Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melodic Based Communication Therapy (MBCT)
Study: 23065117
Drug: Traditional Speech
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Speech and Language Therapy
Study: 9540243
Drug: Treatment-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-based program
Study: 7986972
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg daily for two days
Study: 20886654
Drug: Maitland Grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maitland Grade III anterior‐to‐posterior joint mobilization treatment
Study: 19034470
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis after umbilical cord clamping (Group B)
Study: 2655184
Drug: PY108-068 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY108-068 (150 mg/day in divided doses)
Study: 1026543
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium 200 mg
Study: 20549633
Drug: BDE mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDE mixture DE‐71 at doses of 0.5, 5, and 25 mg kg(‐1) body weight/day for 21 weeks
Study: 17241416
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type B (BTX-B) at doses ranging from 250 to 3,000 U
Study: 2898363
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg day-1
Study: 25661136
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam
Study: 9744143
Drug: Felodipine 5-10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5-10 mg once daily
Study: 23132262
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone (Group G)
Study: 24102416
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg orally each day)
Study: 24102416
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg orally each day)
Study: 8893678
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of estrone sulfate (E1S)
Study: 8893678
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of 17 alpha-dihydroequilin sulfate
Study: 8893678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of E1S and 17 alpha-dihydroequilin sulfate
Study: 11975938
Drug: HMB/Arg/Gln (beta-hydroxy-beta-methylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/Arg/Gln (beta-hydroxy-beta-methylbutyrate 3 g/d, L-arginine 14 g/d, L-glutamine 14 g/d)
Study: 8712393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.2% isoflurane and 30% nitrous oxide in oxygen
Study: 8712393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.4% isoflurane and 30% nitrous oxide in oxygen
Study: 2066595
Drug: HR 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 0.5 g group (0.5 g X 2/day of CPR)
Study: 2066595
Drug: HR 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR 1.0 g group (1.0 g X 2/day of CPR)
Study: 6843050
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg body weight, i.v.)
Study: 22067410
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg three times a day)
Study: 17584826
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel administration
Study: 17584826
Drug: Cumulative docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative docetaxel doses and number of chemotherapy cycles
Study: 12207094
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (2 g NaCl/day)
Study: 12207094
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (20-23 g)
Study: 12207094
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (2 g NaCl/day) after high-salt diet
Study: 12207094
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of dialysis treatment
Study: 29524664
Drug: Cavity shave
Normalized name: Shave Grass Top
DrugBank: Equisetum arvense top (DB14349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavity shave margins excision or re-excision of positive margins; specific details on dosage and duration not available.
Study: 29524664
Drug: High-grade ductal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-grade ductal carcinoma in situ; specific details on dosage and duration not available.
Study: 21564271
Drug: ST(1), no
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST(1), no treatment applied (control)
Study: 2700321
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ketanserin dissolved in the mouth
Study: 4213977
Drug: Empiric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric treatment with carbenicillin and gentamicin
Study: 30955978
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (case group)
Study: 23187956
Drug: Soybean protein
Normalized name: Soybean protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean protein supplement (40g, 89.3 mg isoflavones)
Study: 23187956
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein supplement (40g)
Study: 10778915
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (IHC) for 8 weeks
Study: 10778915
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with IHC
Study: 10778915
Drug: Sputum from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum from COPD patients before treatment with NAC
Study: 8406147
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and ranitidine (300 mg in the evening) for two weeks
Study: 22344742
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg/day, n = 10)
Study: 22344742
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg/day)
Study: 20210263
Drug: Generic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic medications
Study: 7589632
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg SC depot formulation once monthly for 6 months)
Study: 1958438
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 (80 mg)
Study: 1958438
Drug: ICI 169,369
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169,369 (120 mg)
Study: 6752042
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, control group
Study: 31044748
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg/day plus telbivudine (LDT) 600 mg/day
Study: 28710224
Drug: 3-month automated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month automated closed-loop insulin delivery combined with pump suspend feature
Study: 23406253
Drug: Topical medications
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medications with percentage IOP reduction >22.1%
Study: 23406253
Drug: Topical medications
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medications with percentage IOP reduction
Study: 28389316
Drug: Vinflunine (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine (320 mg/m2 or 280 mg/m2 every 21 days)
Study: 21420121
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture therapy
Study: 3311119
Drug: Antibiotic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimen
Study: 6110915
Drug: Oestrogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen treatment
Study: 27049176
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no theophylline)
Study: 24755136
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg before sleep with noise exposure
Study: 24755136
Drug: Control (Lorazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Lorazepam 1 mg before sleep without noise exposure)
Study: 18331216
Drug: Calcium carbasalate
Normalized name: carbasalate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbasalate (380 mg/day)
Study: 18331216
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg/day)
Study: 12763518
Drug: Low-dose HRT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HRT
Study: 1289923
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 200 mg/day intramuscularly
Study: 6377145
Drug: Low-dose prostaglandin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostaglandin E2 vaginal gel
Study: 15801915
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment
Study: 31245006
Drug: High-dose behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose behavioral treatment (24 sessions)
Study: 31245006
Drug: Moderate-dose behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose behavioral treatment (16 sessions)
Study: 30348537
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing
Study: 24657555
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment using RPDs
Study: 19395186
Drug: RT (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (radiation therapy)
Study: 17319791
Drug: Anthracycline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline therapy (PA)